Department of Physiology, National University of Singapore, Singapore.
Adv Drug Deliv Rev. 2010 Jun 15;62(7-8):814-26. doi: 10.1016/j.addr.2010.02.005. Epub 2010 Mar 1.
For acute, chronic, or hereditary diseases of the liver, cell transplantation therapies can stimulate liver regeneration or serve as a bridge until liver transplantation can be performed. Recently, fetal hepatocytes, stem cells, liver progenitor cells, or other primitive and proliferative cell types have been employed for cell transplantation therapies, in an effort to improve the survival, proliferation, and engraftment of the transplanted cells. Reviewing earlier studies, which achieved success by transplanting mature hepatocytes, we propose that there is a switch-like regulation of liver regeneration that changes state according to a stimulus threshold of extracellular influences such as cytokines, matrices and neighboring cells. Important determinants of a successful clinical outcome include sufficient quantities and functional levels of the transplanted cells (even for short periods to alter the environment), rather than just engraftment levels or survival durations of the exogenously transplanted cells. The relative importance of these determining factors will impact future choices of cell sources, delivery vehicles, and sites of cell transplantation to stimulate liver regeneration for patients with severe liver diseases.
对于肝脏的急性、慢性或遗传性疾病,细胞移植疗法可以刺激肝脏再生或作为桥梁,直到可以进行肝移植。最近,已经使用胎儿肝细胞、干细胞、肝祖细胞或其他原始和增殖细胞类型进行细胞移植疗法,以努力提高移植细胞的存活率、增殖率和植入率。通过回顾之前成功进行成熟肝细胞移植的研究,我们提出肝脏再生存在类似于开关的调节,根据细胞外影响(如细胞因子、基质和相邻细胞)的刺激阈值改变状态。成功临床结果的重要决定因素包括足够数量和功能水平的移植细胞(即使是短时间的改变环境),而不仅仅是移植细胞的植入水平或存活时间。这些决定因素的相对重要性将影响未来选择细胞来源、输送载体和细胞移植部位的选择,以刺激严重肝病患者的肝脏再生。